FIELD study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Official Title

Fenofibrate Intervention and Event Lowering in Diabetes

Objective

The objective of this study is to determine the risk of fatal coronary heart disease among subjects with type 2 diabetes who are administered fenofibrate.

Timeline

Timeline
Start Date	01/01/1998
End Date	31/12/2005
Status	Completed

Study Description

Study Description
Study Type	Randomized
Study Details
Condition	Diabetes Mellitus type 2
Intervention	Fenofibrate Placebo
Population Size	9,795

Publications

The administration of fenofibrates among patients with diabetes and either low HDL or hypertension significantly decreased the rate of cardiovascular events. The reduction of cardiovascular events with the administration of fenofibrates was most pronounced among patients with hypertriglyceridemia.^[1]

References

↑ Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D; et al. (2009). “Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study”. Diabetes Care. 32 (3): 493–8. doi:10.2337/dc08-1543. PMC 2646035. PMID 18984774.

[pmid18984774-1] Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D; et al. (2009). “Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study”. Diabetes Care. 32 (3): 493–8. doi:10.2337/dc08-1543. PMC 2646035. PMID 18984774.

[1]